Monoamine oxidase inhibitors for smoking cessation

Medication Treatments for Nicotine Dependence

Volumn , Issue , 2006, Pages 109-121

  Berlin, Ivan ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865129709     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (45)

1. Hare, M.L.C., Tyramine oxidase: a new enzyme system in liver, Biochem. J., 22, 968-979, 1928.
2. Bench, C.J. et al., Measurement of human cerebral monoamine oxidase type B (MAOB) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327, Eur. J. Clin. Pharmacol., 40(2), 169-173, 1991.
3. Chen, K., Wu, H.F., and Shih, J.C., The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical, J. Neurochem., 61(1), 187-190, 1993.
4. Paterson, I.A., Juorio, A.V., and Boulton, A.A., 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system?, J. Neurochem., 55(6), 1827-1837, 1990.
5. Eisenhofer, G., Kopin, I.J., and Goldstein, D.S., Catecholamine metabolism: a contemporary view with implications for physiology and medicine, Pharmacol. Rev., 56(3), 331-349, 2004.
6. Berlin, I. et al., Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects, Br. J. Clin. Pharmacol., 30(6), 805-816, 1990.
7. Berlin, I. and Anthenelli, R.M., Monoamine oxidases and tobacco smoking, Int. J. Neuropsychopharmacol., 4(1), 33-42, 2001.
8. Essman, W.B., Serotonin and monoamine oxidase in mouse skin: effects of cigarette smoke exposure, J. Med., 8(2), 95-101, 1977.
9. Berlin, I., et al., Monoamine oxidase A and B activities in heavy smokers, Biol. Psychiatry, 38(11), 756-761, 1995.
10. Fowler, J.S. et al., Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence, Am. J. Psychiatry, 157(11), 1864-1866, 2000.
11. Fowler, J.S. et al., Inhibition of monoamine oxidase B in the brains of smokers, Nature, 379, 732-736, 1996.
12. Fowler, J.S. et al., Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non-smokers, Nicotine Tob. Res., 1(4), 325-329, 1999.
13. Fowler, J.S. et al., Brain monoamine oxidase A inhibition in cigarette smokers, Proc. Natl. Acad. Sci. USA, 93, 14065-14069, 1996.
14. Fowler, J.S. et al., Low monoamine oxidase B in peripheral organs in smokers, Proc. Natl. Acad. Sci. USA, 100(20), 11600-11605, 2003.
15. Valette, H. et al., Acute inhibition of cardiac monoamine oxidase A following smoke inhalation: Validation study of [11C] befloxatone in rats followed by a PET application in baboons, J. Pharmacol. Exp. Ther. Fast Forward, April 15, 2005 (10.1124/jpet.105.085704).
16. Whitfield, J.B. et al., Monoamine oxidase: associations with alcohol dependence, smoking and other measures of psychopathology, Psychol. Med., 30(2), 443-454, 2000.
17. Berlin, I., Spreux-Varoquaux, O., and Launay, J.M., Platelet monoamine oxidase B activity is inversely associated with plasma cotinine concentration, Nicotine Tob. Res., 2(3), 243-246, 2000.
18. Rose, J.E. et al., Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms, Nicotine Tob. Res., 3(4), 383-390, 2001.
19. Gilbert, D.G. et al., Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence, Nicotine Tob. Res., 5(6), 813-819, 2003.
20. Berlin, I. et al., A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers, Clin. Pharmacol. Ther., 58(4), 444-452, 1995.
21. Fowler, J.S. et al., An acute dose of nicotine does not inhibit MAO-B in baboon brain in vivo, Life Sci., 63(2), PL19-PL23, 1998.
22. Jin Y. et al., Assocation between monoamine oxidase gene polymorphisms and smoking behaviour in Chinese males, Int. J. Neuropsychopharmacol., October 6, 1-8, 2005 [Epub ahead of print].
23. Khalil, A.A., Steyn, S., and Castagnoli, Jr., N., Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves, Chem. Res. Toxicol., 13(1), 31-35, 2000.
24. Yu, P.H. and Boulton, A.A., Irreversible inhibition of monoamine oxidase by some components of cigarette smoke, Life Sci., 41(6), 675-682, 1987.
25. Mendez-Alvarez, E. et al., Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke, Life Sci., 60(19), 1719-1727, 1997.
26. Hauptmann, N. and Shih, J.C.,2-Naphthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity, Life Sci., 68(11), 1231-1241, 2001.
27. Herraiz, T. and Chaparro, C., Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors, Biochem. Biophys. Res. Comm., 326(2), 378-386, 2005.
28. Poindexter, E.H. and Carpenter, R.D., The isolation of harmane and norharmane from tobacco and cigarette smoke, Phytochemistry, 1, 215-221, 1962.
29. Breyer-Pfaff, U. et al., Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking, Life Sci., 58(17), 1425-1432, 1996.
30. Spijkerman, R. et al., The impact of smoking and drinking on plasma levels of norharman, Eur. Neuropsychopharmacol., 12(1), 61-71, 2002.
31. Rommelspacher, H. et al., The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets, Eur. J. Pharmacol., 441(1-2), 115-125, 2002.
32. Fekkes, D. et al., Tryptophan: a precursor for the endogenous synthesis of norharman in man, Neurosci. Lett., 303(3), 145-148, 2001.
33. Eijnden van den, R.J.J.M., Spijkerman, R., and Fekkes, D., Craving for cigarettes among low and light dependent smokers: impact of norharman, Addict. Biol., 8, 463-472, 2003.
34. Villegier, A.S. et al., Transient behavioral sensitization to nicotine becomes longlasting with monoamine oxidases inhibitors, Pharmacol. Biochem. Behav., 76(2), 267-274, 2003.
35. Guillem, K. et al., Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats, J. Neurosci., 25(38), 8593-8600, 2005.
36. Fowler, J.S. et al., Slow recovery of human brain MAO-B after L-deprenyl (selegiline) withdrawal, Synapse, 18(2), 86-93, 1994.
37. Anttila, M. et al., Marked effect of liver and kidney function on the pharmacokinetics of selegiline, Clin. Pharmacol. Ther., 77(1), 54-62, 2005.
38. Berlin, I. and Lecrubier, Y., Food and drug interactions with monoamine oxidase inhibitors: how safe are the newer agents?, CNS Drugs, 5, 403-413, 1996.
39. Berlin, I. et al., Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation, Addiction, 97(10), 1347-1354, 2002.
40. Bodkin, J.A. and Amsterdam, J.D., Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients, Am. J. Psychiatry, 159(11), 1869-1875, 2002.
41. Houtsmuller, E.J., Thornton, J.A., and Stitzer, M.L., Effects of selegiline (L-deprenyl) during smoking and short-term abstinence, Psychopharmacology, 163(2), 213-220, 2002.
42. George, T.P. et al., A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation, Biol. Psychiatry, 53(2), 136-143, 2003.
43. Biberman, R. et al., A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation, Addiction, 98(10), 1403-1407, 2003.
44. Hall, S.M. et al., Extended nortriptyline and psychological treatment for cigarette smoking, Am. J. Psychiatry, 161(11), 2100-2107, 2004.
45. Medioni, J., Berlin, I., and Mallet, A., Increased risk of relapse after stopping nicotine replacement therapies: a mathematical modelling approach, Addiction, 100, 247-254, 2005.